Physician profile
Luis Martinez
NPI 1972605533
$3,293.42
in general payments reported to CMS, 2019-2025
35 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $107 · 2021: $239 · 2022: $323 · 2023: $488 · 2024: $1,327 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Travel and Lodging: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.34 |
| Travel and Lodging | $853.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,159.49 | 2024 | |
| Novo Nordisk INC | $414.41 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $246.62 | 2023-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.31 | 2019-2021 | |
| Sight Sciences, INC. | $142.38 | 2023 | Omni Surgical System |
| Astrazeneca Uk Limited | $135.00 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $134.57 | 2023-2024 | Austedo Xr |
| Pfizer INC. | $124.50 | 2019-2025 | |
| Exact Sciences Corporation | $100.58 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $79.26 | 2019-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $74.64 | 2021-2022 | |
| Abbvie INC. | $73.47 | 2021-2023 | |
| Abbott Laboratories | $72.47 | 2022 | |
| Intuitive Surgical, INC. | $60.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.90 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.64 | 2021-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $38.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.91 | 2020-2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $34.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.64 | 2025 | Vpriv |
| Novartis Pharmaceuticals Corporation | $23.08 | 2025 | |
| Gilead Sciences, INC. | $18.49 | 2019 | |
| Astellas Pharma US INC | $16.33 | 2020 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.